Verutex [clinicaltrials_resource:NCT00718315/group/P3]
Participants received erlotinib 150 mg daily and a thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days.
participant flow for clinicaltrials:NCT00718315 [clinicaltrials_resource:8622476b6329e0c0083afa555b416ab7]participant counts in P3 for milestone 2 of NCT00718315 [clinicaltrials_resource:NCT00718315/milestone/1/p/3]participant counts in P3 for milestone 3 of NCT00718315 [clinicaltrials_resource:NCT00718315/milestone/2/p/3]participant counts in P3 for milestone 4 of NCT00718315 [clinicaltrials_resource:NCT00718315/milestone/3/p/3]Adverse Event [clinicaltrials_resource:NCT00718315/withdraw/1]Death [clinicaltrials_resource:NCT00718315/withdraw/2]Lost to Follow-up [clinicaltrials_resource:NCT00718315/withdraw/3]Protocol Violation [clinicaltrials_resource:NCT00718315/withdraw/4]Erlotinib dose decreased [clinicaltrials_resource:NCT00718315/withdraw/5]Use of Minocyclin [clinicaltrials_resource:NCT00718315/withdraw/6]Disease progression [clinicaltrials_resource:NCT00718315/withdraw/7]Unknown [clinicaltrials_resource:NCT00718315/withdraw/8]Use of ATB and Corticoids [clinicaltrials_resource:NCT00718315/withdraw/9]
group [clinicaltrials_vocabulary:group]
Verutex [clinicaltrials_resource:NCT00718315/group/P3]
Participants received erlotinib 150 mg daily and a thin film of the topical formulation of Verutex was applied to face, neck, and anterior and posterior chest twice daily (every 12 hours), as per medical guidance daily for 30 days.
Bio2RDF identifier
NCT00718315/group/P3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00718315/group/P3
group id [clinicaltrials_vocabulary:group-id]
description
Participants received erlotini ...... l guidance daily for 30 days.
@en
identifier
clinicaltrials_resource:NCT00718315/group/P3
title
Verutex
@en
type
label
Verutex [clinicaltrials_resource:NCT00718315/group/P3]
@en